Sign In
Buy RAPT
$58.02
+0 (+0%)
At Close: Jun 01, 2026
7 ‘Strong Buy' Biotech Stocks to Rejuvenate Your Portfolio
09:24pm, Wednesday, 27'th Sep 2023
While the health innovation space presents wild risks, you could potentially swing the odds in your favor with strong buy biotech stocks. Specifically, these ideas represent publicly traded biotechnol
RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in September
04:05pm, Wednesday, 30'th Aug 2023
SOUTH SAN FRANCISCO, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and co
RAPT Therapeutics: Major Catalysts Are A Long Way Off
03:59pm, Tuesday, 13'th Jun 2023
RAPT Therapeutics has solid data from early trials but has a habit of going down on good data. One reason could be that the stock is heavily institution-owned. Their next major catalyst is one year aw
RAPT Therapeutics to Participate in the Goldman Sachs Global Healthcare Conference
08:00am, Wednesday, 07'th Jun 2023
SOUTH SAN FRANCISCO, Calif., June 07, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and co
-FLX475-treated patients exhibited significant changes in immune pathways likely to enhance an antitumor response -FLX475 modifies the tumor microenvironment (TME) to resemble those of responders to a
RAPT Therapeutics: Potential Strong Upside Ahead
12:12am, Thursday, 30'th Mar 2023
RAPT Therapeutics, Inc. is a clinical-stage biotech developer of specific small molecules that can modulate the critical immune drivers of inflammatory diseases and oncology. The pipeline of investiga
What Makes Rapt Therapeutics (RAPT) a Good Fit for 'Trend Investing'
10:33am, Thursday, 23'rd Feb 2023
Rapt Therapeutics (RAPT) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it th
Wall Street Analysts Think Rapt Therapeutics (RAPT) Could Surge 66.77%: Read This Before Placing a Bet
11:18am, Friday, 10'th Feb 2023
The mean of analysts' price targets for Rapt Therapeutics (RAPT) points to a 66.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement amon
Here's Why 'Trend' Investors Would Love Betting on Rapt Therapeutics (RAPT)
10:33am, Wednesday, 25'th Jan 2023
Rapt Therapeutics (RAPT) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it th
RAPT Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
08:00am, Tuesday, 03'rd Jan 2023
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing a
RAPT Therapeutics to Present FLX475 Phase 1/2 Data at the European Society for Medical Oncology (ESMO) Immuno-Oncology Annual Congress
07:05pm, Wednesday, 30'th Nov 2022
SOUTH SAN FRANCISCO, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT” or the “Company”), a clinical-stage, immunology-based biopharmaceutical company f
Why RAPT Therapeutics (RAPT) Stock Might be a Great Pick
09:47am, Tuesday, 22'nd Nov 2022
RAPT Therapeutics (RAPT) has seen solid earnings estimate revision activity over the past two months, and belongs to a strong industry as well.
RAPT Therapeutics Strengthens Leadership Team with Two New Key Hires
12:00pm, Wednesday, 28'th Sep 2022 GlobeNewswire Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 28, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developin
Rapt Therapeutics (RAPT) Upgraded to Buy: Here's What You Should Know
04:00pm, Friday, 23'rd Sep 2022 Zacks Investment Research
Rapt Therapeutics (RAPT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Here's Why Rapt Therapeutics (RAPT) Looks Ripe for Bottom Fishing
01:55pm, Friday, 23'rd Sep 2022 Zacks Investment Research
After losing some value lately, a hammer chart pattern has been formed for Rapt Therapeutics (RAPT), indicating that the stock has found support. This, combined with an upward trend in earnings estima
